Uromigos Live 2024 Perioperative UC Panel Part 4: Predicting the Future of Muscle Invasive Bladder Cancer After NIAGARA

By Thomas Powles, MBBS, MRCP, MD, Andrea B. Apolo, MD, Shilpa Gupta, MD, Kala Sridhar, MD, Petros Grivas, MD, PhD - Last Updated: October 14, 2024

Drs. Powles, Apolo, Grivas, Gupta, and Sridhar wrap up the first panel session in bladder cancer by discussing what they each anticipate individually for the future of treatment post the NIAGARA trial.

Watch the first segment of this panel: NIAGARA Trial for MIBC – Strengths and Weaknesses

Bladder-Sparing Innovations in MIBC: Dr. Elizabeth Plimack on the RETAIN Approach and Its Future

Elizabeth Plimack, MD, MS, FASCOMuscle Invasive Urothelial Carcinoma | March 17, 2025

Dr. Plimack details RETAIN, from early findings with neoadjuvant ddMVAC to the evolution of RETAIN-1 and RETAIN-2.

Disitamab Vedotin Plus Toripalimab Shows Promise as Neoadjuvant Therapy in HER2-Expressing MIBC

Emily MenendezMuscle Invasive Urothelial Carcinoma | February 20, 2025

Preliminary results of the study showed promising efficacy and safety with neoadjuvant treatment with DV plus toripalimab.

RETAIN-2: Risk-Enabled Therapy After Neoadjuvant Chemo-Immunotherapy for MIBC

Pooja Ghatalia, MDMuscle Invasive Urothelial Carcinoma | February 20, 2025

Drs. Ghatalia and Nizam break down in detail the RETAIN-2 study, a phase 2 trial of risk enabled therapy for MIBC.

NIAGARA: Impact of pCR on Long-Term Outcomes

Matthew Galsky, MDMuscle Invasive Urothelial Carcinoma | February 14, 2025

Dr. Galsky highlights the latest findings on the impact of pCR on long-term outcomes in the NIAGARA trial.

CheckMate 274: Additional Efficacy Outcomes in Patients With MIBC

Matthew Galsky, MDMuscle Invasive Urothelial Carcinoma | February 20, 2025

Dr. Galsky provides comment on the additional efficacy outcomes in patients with MIBC from the CheckMate 274 study.

Uromigos Live 2024 Perioperative UC Panel Part 4: Predicting the Future of Muscle Invasive Bladder Cancer After NIAGARA

Related Posts